[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"RWTH Aachen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":456},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,45,68,99,124,150,180,201,222,246,269,291,323,349,373,410,432],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100311406","phase-2-prospective-randomized-trial-of-personalized-medicine-with-pentaglobin-after-surgical-infectious-source-control-in-patients-with-peritonitis-100311406",false,"NCT03334006","Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis","PEPPER","Inclusion Criteria:\n\n1. The patient is diagnosed with secondary or quaternary peritonitis\n2. The time of the surgical infectious source control is within 6 hours of indication (defined as date and time of registration for surgical or minimal invasive procedure).\n3. Sepsis and \u002F or septic shock (according to the current sepsis guideline of the German Sepsis Society).\n4. SOFA Score ≥ 8\n5. The concentration of IL-6 is ≥ 1000 pg \u002F ml\n6. Treatment with antibiotics is started within 12 hours of admission to the Intensive Care Unit\n7. The informed consent form has been signed by the patient and \u002F or by his legal representative (such as his spouse, an health care proxy authorized or a legal representative) or by a consultant physician\n\nExclusion criteria\n\n1. Patients with a life expectancy of less than 90 days due to medical conditions unrelated to peritonitis nor with sepsis and \u002F or septic shock.\n2. For female patients: The patient is pregnant or breastfeeding.\n3. The patient is a minor (\\\u003C 18 years of age).\n4. The patient has known chronic renal dysfunction requiring dialysis (creatinine ≥ 3.4 mg \u002F dl or creatinine clearance ≤ 30 mL\u002Fmin\u002F1.73 m²).\n5. The patient has acute, primarily non-infectious pancreatitis or mediastinitis.\n6. The patient has a BMI \\> 40.\n7. The patient has any contraindication to study drug.\n8. The patient has participated in another clinical trial within the last 30 days.\n9. The patient is in a dependent or employment relationship with the sponsor or investigator.\n10. The patient is institutionalized by court or government order.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The aim of this prospective, randomized, controlled trial is to provide evidence for adjuvant IgGAM treatment with regard to\n\n1. Improvement of patient outcomes for peritonitis. Improvement in outcome will be determined by scores such as MOF, SOFA and survival.\n2. Identification of biomarkers (including immunoglobulin levels, HLA-DR, NF-kB1 and other immunological biomarkers) to identify patient subpopulations that benefit most from IgGAM treatment. These patients will form the basis for a further randomized, controlled, double-blind Phase III trial (RCT) to demonstrate the benefit of this treatment.\n3. In addition, these biomarkers could help to guide a targeted, i.e. \"personalized\", adjuvant therapy with Pentaglobin® (IgGAM) in the indication of peritonitis.",[26,27,28],"Peritonitis","Sepsis","Septic Shock",[30,31],"Pentaglobin®","Personalized Medicine","RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-11","ACTUAL",{"date":38,"type":36},"2017-11-20",{"date":40,"type":20},"2028-03",{"name":42,"class":43},"RWTH Aachen University","OTHER",20,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100439024","adjuvant-stereotactic-body-radiation-therapy-after-trans-arterial-chemoembolization-in-hepatocellular-carcinoma-100439024","NCT04996914","Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma","ASTrH","Inclusion Criteria:\n\n* HCC (diagnosis: histological or radiological)\n* Age: 18-80\n* Number of lesions 1-3 lesions\n* Size of the lesion (or sum of 2-3 lesions) ≥ 4 cm\n* Sufficient non-tumorous liver volume (≥ 800 cm3)\n* Child Pugh Score: A5-6 or B7-8\n* BCLC A or B\n* Patient is illegible or refused surgical resection or orthotopic liver transplant\n* Blood work (within 2 weeks before registration):\n* Absolute neutrophil count (ANC) ≥ 1,500 cells\u002Fmm³)\n* Platelets ≥50,000 cells\u002Fmm³\n* AST (and ALT) \\\u003C 5 times ULN\n* Serum creatinine ≤ ULN or creatinine clearance ≥ 50 mL\u002Fmin\n\nExclusion Criteria:\n\n* Evidence of extrahepatic disease (lymph node or distant metastases)\n* Evidence of macroscopic vascular invasion\n* Evidence of an arterio-portal or arterio-venous fistulas\n* History of previous malignancy\n* Previous SIRT\n* Previous Sorafenib in the last 8 weeks\n* Pregnant and lactating females","80 Years",{"count":54,"type":20},30,[56],"NA","The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.",[59],"Hepatocellular Carcinoma Non-resectable","2026-05-05",{"date":62,"type":36},"2026-05-11",{"date":60,"type":36},{"date":65,"type":20},"2029-05-05",{"name":42,"class":43},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100626236","german-dementia-registry-100626236","NCT07433010","German Dementia Registry","DemReg","Inclusion Criteria:\n\nInclusion Criteria for Patient:\n\n* Ability of the participant and\u002For his\u002Fher legally authorized representative (e.g., spouse or legal guardian), as appropriate and applicable, to understand the purpose and risks of the register and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local privacy regulations.\n* Participating patients must have a diagnosis of SCD, MCI or early dementia of different etiology (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy-Body Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Normal Pressure Hydrocephalus, Major Depression; Vascular Dementia; TDP-43 associated limbic encephalopathy (LATE), Mixed Dementia AD + VaD, Prion-Associated Dementia) together with biomarkers such as cerebrospinal fluids (CSF) amyloid beta 1-42, amyloid beta 1-40, amyloid beta 1-42\u002Famyloid beta 1-40 ratio, total tau and phosphorylated tau, amyloid or tau imaging.\n* At least 18 years of age.\n\nInclusion Criteria for family member:\n\n* At least 18 years of age.\n* Patient was included in the registry\n* Family member is strongly involved to the patient's life according to the patient's statement\n* Ability of the participant, as appropriate and applicable, to understand the purpose and risks of the register\n\nExclusion Criteria:\n\nExclusion Criteria for Patient:\n\n* Unwilling to provide informed consent.\n* No available biomarkers such as cerebrospinal fluids (CSF) amyloid beta 1-42, amyloid beta 1-40, amyloid beta 1-42\u002Famyloid beta 1-40 ratio, total tau and phosphorylated tau, amyloid or tau imaging.\n\nExclusion Criteria for family member:\n\n* Unable or unwilling to provide informed consent.",{"count":76,"type":20},5000,"20 Years","OBSERVATIONAL","The German Dementia Registry (DEMREG) is a large-scale national prospective biomarker-based study for cognitive impairment and dementia, providing an integrated clinical research platform for research studies.",[81],"Dementia Disorder",[83,84,85,86,87,88,89],"Dementia","Registry","Biomarkers","Neurodegeneration","Natural history","Treatment","Mild Cognitive Impairment","2026-02-18",{"date":92,"type":36},"2026-02-25",{"date":94,"type":36},"2022-05-16",{"date":96,"type":20},"2099-12",{"name":42,"class":43},24,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":67},"100455523","diaphragm-atrophy-and-dysfunction-in-mechanical-ventilation-100455523","NCT05211661","Diaphragm Atrophy and Dysfunction in Mechanical Ventilation","Development of Diaphragm Atrophy, Dysfunction and Inhibited Cortical Control in Mechanical Ventilation","DAM","Inclusion Criteria:\n\n* Initiation of invasive mechanical ventilation in the Intensive Care Unit within 48 hours.\n* Expected duration of invasive mechanical ventilation of at least 5 days.\n\nExclusion Criteria:\n\n* Body-mass-index (BMI) \\>40\n* Expected absence of active participation of the patient in study-related measurements after extubation\n* Alcohol or drug abuse\n* Non MRI compatible implant in the body\n* Slipped disc\n* Epilepsy\n* Patients in an interdependence or with an employment contract with the principal investigator, Co-PI or his deputy.","75 Years",{"count":109,"type":20},15,"The gold standard of twitch transdiaphragmatic pressure recordings would ultimately clear the fog around the rate of development of Ventilator induced Diaphragm Dysfunction (VIDD) in mechanically ventilated patients over time.\n\nThrough measurements made even after mechanical ventilation (MV) it could be clarified to what extent patients recover from VIDD.\n\nPaired with cortical stimulation and electromyographic recordings of diaphragm muscle potentials, it could be explored to what extent decreased diaphragm excitability due to long term MV contributes to VIDD on the level of motor cortex.\n\nAgainst that background the present project aims at determining the rate of decline in diaphragm function, strength and control in patients undergoing MV (including measurements after extubation).",[112,113,114,115],"Diaphragm Issues","Mechanical Ventilation Complication","Respiratory Failure","Intensive Care (ICU) Myopathy","2026-02-04",{"date":118,"type":36},"2026-02-09",{"date":120,"type":36},"2022-10-10",{"date":122,"type":20},"2028-06-01",{"name":42,"class":43},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":78,"phases":4,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":67},"100617759","smoking-cessation-before-bronchoscopy-or-ct-guided-puncture-100617759","NCT07322796","Smoking Cessation Before Bronchoscopy or CT-guided Puncture","Smoking Cessation Before Intervention in Patients With Pulmonary Nodules Requiring Further Diagnosis","Inclusion Criteria:\n\n* The patient is an active smoker by the time of the initial presentation in our pneumological outpatient clinic for the clarification of a suspicious nodule\n\nExclusion Criteria:\n\n* Current or past medically relevant illness or treatment that could affect the evaluability of the study.\n* Expected lack of willingness to actively participate in study-related measures.",{"count":132,"type":20},25,"3 Months","Nicotine is the most common preventable cause of death and is responsible for over seven million deaths worldwide. If current trends continue, tobacco will kill more than eight million people worldwide every year by 2030. Smoking tobacco products is the most important risk factor for the development of lung cancer. Passive smoking is also a major cause of lung cancer. Since July 2024, smokers and former smokers have been able to receive a low-radiation CT scan under certain conditions to detect lung cancer at an early stage. It is therefore to be expected that the number of diagnoses of pulmonary lesions or nodules will increase in the near future. The risk of developing and dying from tobacco-related diseases is reduced once nicotine cessation begins. Screening all patients for tobacco use, e-cigarette use, and providing behavioral counseling and pharmacotherapy to quit smoking are among the most valuable preventive services we can offer in healthcare.\n\nNicotine dependence can be estimated using the so-called Fagerström test. An additional evaluation of nicotine behavior can be carried out by testing cotinine in urine, a method that is used, for example, in the listing for lung transplantation. Cotinine is a degradation product of nicotine that can be detected in the urine of smokers and passive smokers. Cotinine levels in urine depend on the frequency and quantity of nicotine consumption. The half-life of cotinine is 16 to 22 hours, which means that half of the cotinine is excreted from the body after this time. Another marker that can be used as a measure of tobacco consumption is carboxyhaemoglobin (COHb). This is hemoglobin with carbon monoxide at the binding site for oxygen. The reference range for carboxyhaemoglobin is 0.4 - 1.6 %. In smokers, values of 3-10 % are still considered normal.\n\nIn our department, the smoking status of patients is assessed upon first contact. Support options for smoking cessation are offered and, upon request, initiated. Previous studies have shown that smoking is a risk factor for complications after thoracic surgical procedures and that patients who underwent thoracic surgery quit smoking almost twice as often compared to patients who did not undergo surgery. However, to the best of our knowledge, there is currently no study regarding smoking cessation before intervention in patients with nodules needing clarification (bronchoscopy or CT-guided puncture).\n\nTherefore, the aim of the study is to support and monitor smoking cessation before intervention in patients with nodules needing further diagnosis (bronchoscopy or CT-guided puncture).",[136,137],"Pulmonary Nodule, Solitary","Smoking Behaviors",[139,140,141],"smoking","smoking cessation","pulmonary nodules","2026-01-26",{"date":144,"type":36},"2026-01-28",{"date":146,"type":36},"2026-01-01",{"date":148,"type":20},"2027-12-31",{"name":42,"class":43},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":160,"conditions":161,"keywords":168,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":67},"100508636","diaphragmatic-function-as-a-biomarker-100508636","NCT05903001","Diaphragmatic Function as a Biomarker","Diaphragmatic Function as a Biomarker in Patients With Respiratory Diseases","DFUNBIO","Inclusion Criteria:\n\n* patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension\n* is 18 years or older\n* is mentally and physically able to understand the study and to follow instructions\n* are legally competent\n* signed declaration of consent\n\nExclusion Criteria:\n\n* BMI \\> 35\n* current or treatments or diseases in the past which could influence the evaluation of the study\n* Expected lack of willingness to actively participate in study-related measures\n* alcohol or drug abuse\n* disc herniation\u002Fprolapse\n* epilepsy\n* wheelchair bound\n* in custody due to an official or court order\n* in a dependent relationship or employment relationship with investigating physician or one of their deputy\n* emergency inpatient hospital stay within 4 weeks before study-specific examinations",{"count":159,"type":20},800,"Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.",[162,163,164,165,166,167],"Dyspnea; Asthmatic","COPD","Fibrosis","Pulmonary Hypertension","Asthma","Dyspnea",[169,163,170,171,172,173],"dyspnea","asthma","fibrosis","pulmonary hypertension","pneumology",{"date":144,"type":36},{"date":176,"type":36},"2023-07-01",{"date":178,"type":20},"2026-12-30",{"name":42,"class":43},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":188,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":67},"100427730","sympathetic-nerve-activity-predictors-in-patients-with-chronic-obstructive-pulmonary-disease-100427730","NCT04849806","Sympathetic Nerve Activity Predictors in Patients With Chronic Obstructive Pulmonary Disease","Dissecting the Nature and Determinants of Sympathetic Nerve Activity in Patients With COPD","SNAP-COPD","Inclusion Criteria:\n\n* Age ≥ 18\n* Ability and willingness to give informed consent to participate in the study\n\nExclusion Criteria:\n\n* Atrial fibrillation\n* Active pacing of the heart by a cardiac pacemaker (i.e. no intrinsic heart rate)\n* Clinically pre-established cardiovascular disease (e.g. arterial hypertension or systolic heart failure)\n* In-patient stay in the hospital within the last 4 weeks prior to the study examination date",true,{"count":190,"type":20},135,"The project will be pursued in our respiratory, autonomic nervous system physiology laboratory (Respiratory, autonomic nervous system physiology laboratory, Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital; Head of Department: Professor Michael Dreher).\n\nOveractivity of the sympathetic nerve activity (SNA) axis with \"centrally\" increased heart rate and peripheral vasoconstriction is a known phenomenon in patients with systolic heart failure (HF) and has recently been described in patients with primary lung disease as seen in chronic obstructive pulmonary disease (COPD).\n\nHowever, systematic analyses on this clinically relevant topic are currently lacking.\n\nThus, using a comprehensive, multimodal approach and state-of-the-art technology, this research project is designed to determine the extent and nature of increased SNA in COPD (AIM 1) and evaluate the underlying mechanisms (AIM 2).\n\nThe project will address the following hypotheses:\n\n1. In COPD, concomitant obstructive sleep apnea is independently associated with increased SNA.\n2. Precapillary pulmonary hypertension (PH), inspiratory muscle dysfunction and systemic inflammation describe a COPD phenotype characterised by increased SNA with a different subtype.",[163,193,194],"Sympathetic Nervous System Diseases","Catecholamine; Overproduction",{"date":144,"type":36},{"date":197,"type":36},"2022-05-10",{"date":199,"type":20},"2028-12",{"name":42,"class":43},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":188,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":208,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},"100412798","translational-investigation-of-the-glutamatergic-and-gabaergic-system-in-schizophrenia-100412798","NCT04655235","Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia","Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia - a Combined EEG-, FMRI-, Genetic, Serological and Cell Biological Study","PATIENTS\n\nInclusion Criteria:\n\n* diagnosis of schizophrenia according to DSM-5\n* aged 18 to 80\n* being mentally and contractually capable to give their consent to study participation\n\nExclusion Criteria:\n\n* pregnancy\n* structural neurological disease\n* a further psychiatric comorbidity that dominates in the clinical appearance\n\nHEALTHY PARTICIPANTS\n\nInclusion Criteria:\n\n* aged 18 to 80\n* being mentally and contractually capable to give their consent to study participation\n\nExclusion Criteria:\n\n* pregnancy\n* structural neurological disease\n* psychiatric disorder\n* for healthy controls: psychiatric disorders in the family history of first-degree relatives",{"count":209,"type":20},600,"In the last years, the imbalance between excitatory and inhibitory neuronal activity has come to the fore as a possible molecular disease mechanism of schizophrenia . Pharmacological studies have suggested different fMRI and EEG markers of that molecular dysfunction (resting state connectivity changes, auditory mismatch and steady state deficits). However, previous research is inconclusive regarding their genetic basis, their reliability, inter-individual relationship as well as disease specificity. Therefore, in this study we aim at estimating the effect sizes, test-retest-reliability and clinical correlates of the respective markers in a comparative fashion in patients with schizophrenia, their relatives and healthy control subject. To assess their molecular validity, we will assess their relationship with glutamatergic and GABAergic genotypes and cellular disease models. The proof of such a relation would give the opportunity of detecting a glutamatergic and GABAergic imbalance throughout non-invasive imaging. Furthermore, it would help deepening our understanding of the molecular pathophysiology of mental disorders which will be essential for the development of more effective drugs.",[212],"Schizophrenia","2025-03-11",{"date":215,"type":36},"2025-03-14",{"date":217,"type":36},"2021-10-01",{"date":219,"type":20},"2030-03",{"name":42,"class":43},3,{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":230,"targetDuration":231,"studyType":78,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":67},"100386354","autonomic-small-fiber-neuropathy-and-ehlers-danlos-syndromes---prospective-study-and-registry-100386354","NCT04310644","Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry","Autonomic Neuropathy and Its Pathophysiology in Autoimmune Autonomic Neuropathies, Postural Orthostatic Tachycardia Syndrome and Ehlers Danlos Syndromes: Peripheral Autonomic Small Fiber Neuropathy or Central Autonomic Failure? Validation of the Malmö POTS Score and a Better Diagnosis of POTS in Patientes With Autnomic Failure (VaGeMAPS-3-step-Diag)","ProANS","Inclusion Criteria:\n\n* autonomic neuropathy\n* Postural orthostatic tachycardia syndrome\n* hypermobile or classical Ehlers Danlos syndromes\n* Chronic fatigue syndrome, mast cell activation syndrome and\u002For PostCOVID\n* healty controls\n* between 18-80 years\n* in patients: diagnosis and clinical testing in our outpatient clinic\n* German speaking\n\nExclusion Criteria:\n\n* pregnancy\n* Pacemaker or Deep brain Stimulation\n* sensory or motor Polyneuropathy\n* neurodegenerative disease",{"count":19,"type":20},"5 Years","We examine patients with different autonomic neuropathies and Ehlers Danlos syndromes compared to healthy controls at three different points over time (baseline, after 3 months and after 1.5 years) to gain knowledge about the course of this disease and understand its pathophysiology, with a focus on Small Fiber neuropathy. Moreover we will validate the german version of the Malmö POTS Score and establish an easy diagnostic scheme for patients in outpatient care.",[234,235,236,237],"Autonomic Neuropathy","Ehlers-Danlos Syndrome Hypermobility Type","Small Fiber Neuropathy","Postural Tachycardia Syndrome","2025-02-03",{"date":240,"type":36},"2025-02-04",{"date":242,"type":36},"2019-09-15",{"date":244,"type":20},"2029-09-15",{"name":42,"class":43},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":254,"targetDuration":256,"studyType":78,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":67},"100422486","evaluating-the-treatment-in-the-mzeb-aachen-100422486","NCT04781452","Evaluating the Treatment in the MZEB Aachen","Evaluating the Treatment in the the Center for Disabled People in Aachen (MZEB Aachen) - a Registry on Patients With Severe Disabilities","EvalMZEB","Inclusion Criteria:\n\n* intellectual disability and\u002For severe multiple disability (disability degree GdB at least 70 and at least one noticeable sign\n* willing to participate\n\nExclusion Criteria:\n\n* housed in an Institution and\u002For prison",{"count":255,"type":20},2000,"10 Years","Evaluation of patient characteristics, involved physicians and therapists as well as therapies in a German University Center for the Treatment of patients with intellectual disabilities and severe multiple disability (MZEB Aachen)",[259,260],"Intellectual Disability","Disability Physical","2024-06-21",{"date":263,"type":36},"2024-06-24",{"date":265,"type":36},"2019-07-01",{"date":267,"type":20},"2029-07-01",{"name":42,"class":43},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":67},"100310579","bio-2-heart-identification-of-biomarkers-in-t2dm-and-heart-failure-100310579","NCT03323216","BIO-2-HEART: Identification of Biomarkers in T2DM and Heart Failure","BIO-2-HEART Study (Identifying New BIOmarkers in Patients With Type 2 Diabetes Mellitus and HEArt Failure Receiving Cardiac Resynchronization Therapy Device Implantation)","BIO-2-HEART","Inclusion Criteria:\n\n1. guideline-appropriate clinical indication for CRT implantation\u002Felectrophysiologial examination\u002Fpulmonary vein ablation\n2. age of majority\n3. written declaration of consent\n4. persons who are able to work and mentally able to follow the instructions of the study staff\n5. free access routes\n\nExclusion Criteria:\n\n1. anemia Hb \\\u003C8 mg \u002F dl\n2. patients with acute infectious disease (e.g. pneumonia)\n3. non-intubatable coronary sinus\n4. patients who do not have access to the subclavian vein (e.g. thrombosis of the subclavian vein or superior vena cava)\n5. patients with idiopathic hypertrophic, restrictive or constrictive cardiomyopathy, or heart failure due to a known inflammatory or infiltrating disease (e.g. amyloidosis, sarcoidosis) or a constrictive disease\n6. patients with heart failure by sepsis\n7. persons with acute myocardial ischaemia, e.g. by angina pectoris or ECG changes under load\n8. patients with acute coronary syndrome are not implanted in the past 3 months\n9. patients who were hospitalized during the last month due to heart failure and who had to be treated intravenously with diuretics or inotropic substances\n10. patients with mechanical aortic valve or tricuspid valve\n11. patients with heart transplant.\n12. patients with acute liver or renal failure\n13. pregnant and lactating women\n14. patients placed under an official or judicial order in an institution\n15. patients who are in a dependency or employment relationship with the sponsor or auditor\n16. taking an investigational medicinal product 30 days before the start of the study",{"count":278,"type":20},400,"The primary aim of the current study is a better understanding of the role of Type 2 Diabetes Mellitus (T2DM) in heart failure and, in particular, changes in cardiac metabolism, which may contribute to heart failure. Various biomarkers in the coronary artery blood, as well as in the arterial and peripheral venous blood, are to be identified for this purpose. Included are patients with and without T2DM and with or without heart failure (HFpEF, HFmrEF, HFrEF), who have a clinically indicated and guidance-appropriate Cardiac Resynchronisation Therapy (CRT) implantation or pulmonary vein ablation\u002Felectrophysiological examination.\n\nNot all patients currently benefit from the implantation of a CRT system (so-called non-responder). Despite narrow inclusion criteria, these \"non-responders\" cannot be unmasked in advance of the implantation. A further aim of this study is to identify biomarkers, which can be determined in advance of implantation to differentiate between responders and non-responders.",[281,282],"Heart Failure","Diabetes Mellitus, Type 2","2024-05-07",{"date":285,"type":36},"2024-05-09",{"date":287,"type":36},"2018-04-01",{"date":289,"type":20},"2026-12-31",{"name":42,"class":43},{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":256,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":21,"phases":301,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":314,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":67},"100546088","prevention-programme-for-improvement-of-well-being-and-level-of-participation-in-adolescents-with-enhanced-psychiatric-burden-in-the-school-environment-100546088","NCT06390384","Prevention Programme for Improvement of Well-being and Level of Participation in Adolescents With Enhanced Psychiatric Burden in the School Environment.","STEPS@SCHOOL","Inclusion Criteria:\n\n* Children and adolescents of both genders (w : m = 1 : 1) aged from 10 to 14 years\n* Psychiatric symptoms characterized using SDQ-25 with the cutoff \\> 17\n* Regular school attendence\n\nExclusion Criteria:\n\n* IQ \\\u003C80, ongoing psychiatric or psychotherapeutic treatment with regular appointments (at least once a month).","14 Years",{"count":300,"type":20},100,[56],"The objectives of this two-arm phase-IIa randomized, controlled study are:\n\n* to prove whether the combination of a clinic-guided personal counseling with a therapy-assistive digital support (blinded care approach) and a training of digital and mental health literacy is superior to a teacher-guided training of digital and mental health literacy only (treatment as usual) concerning the reduction of psychiatric burden in adolescents.\n* to improve the well-being and level of participation in adolescents at risk for psychiatric disorders.\n* to reduce the expression of psychiatric symptoms in adolescents with enhanced psychiatric burden.\n* to test whether the combination of a clinic-guided personal counseling with a therapy-assistive digital support is well accepted by students, their parents, and teachers.\n* to identify individual factors predicting the improvement of well-being and level of participation in adolescents as well as the acceptance of the prevention program in all subjects involved (students, parents, teachers, psychologists).\n* to investigate whether the clinic-guided personal counseling with a therapy-assistive digital support causes reduction of primary and secondary costs in the psychosocial support system and represents an economic advantage.",[304,305,306],"Blended-care Counselling","Digital and Mental Literacy Training","App STEPS",[308,309,310,311,312,313],"eMental health","digital health","blended care treatment","students at risk in schools","psychiatric disorders","adolescents","NOT_YET_RECRUITING","2024-04-25",{"date":317,"type":36},"2024-04-30",{"date":319,"type":20},"2026-08-01",{"date":321,"type":20},"2028-12-31",{"name":42,"class":43},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":333,"conditions":334,"keywords":337,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":67},"100520788","non-invasive-differentiation-of-supraventricular-tachyarrhythmia-100520788","NCT06061120","Non-invasive Differentiation of Supraventricular Tachyarrhythmia","Non-invasive Differentiation of Supraventricular Tachyarrhythmias by Questionnaire and High-resolution ECG in the Context of Ablation Treatment","NIDSA","Inclusion Criteria:\n\n* Scheduled for ablation of a supraventricular tachycardia (atrial fibrillation, typical atrial flutter, AV nodal reentry tachycardia, accessory pathway)\n* majority\n\nExclusion Criteria:\n\n* Unstable patient with need for intensive medical care\n* Lack of language skills or limited cognitive abilities that prevent a differentiated anamnesis and information.\n\nExclusion criteria for study section Questionnaire:\n\n\\- Competing clinically present arrhythmias, including relevant supra- and ventricular extrasystole (\\>5%\u002Fdie).\n\nExclusion criteria for study section Extended high-resolution ECG:\n\n* Previous electrophysiological ablation at the same site for atrial fibrillation.\n* Relevant supra- and ventricular extrasystole (\\>5%\u002Fdie).\n* Other clinically present arrhythmias are not excluded if they can be sequentially triggered and ablated (e.g. atrial fibrillation and atrial flutter). Since separate detection is possible with the high-resolution ECG.\n* Implanted active electrical device (e.g. pacemaker, defibrillator, deep brain pacemaker)\n* Allergy to measuring electrodes",{"count":332,"type":20},1250,"1. Questionnaire for supraventricular tachycardia: About history and targeted diagnosis of supraventricular tachycardia\n2. Extended Signal-averaged ECG for detailed P-Wave analysis and to calculate a virtual atrial electrocardiogram (ECG)",[335,336],"Supraventricular Arrhythmia","Atrial Fibrillation",[338,339,340,335,336],"Electrocardiogram","Signal-averaged P-Wave","Questionnaire","2023-09-24",{"date":343,"type":36},"2023-09-29",{"date":345,"type":36},"2021-09-01",{"date":347,"type":20},"2026-09-30",{"name":42,"class":43},{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":21,"phases":357,"briefSummary":358,"conditions":359,"keywords":363,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":67},"100365082","fasciotens-to-treat-an-open-abdomen---a-prospective-cohort-study-100365082","NCT04033614","Fasciotens to Treat an Open Abdomen - a Prospective Cohort Study","Fasciotens","Inclusion Criteria:\n\n* Laparostoma with a resorbable net and planned or necessary \"second look\" operation.\n* Age of majority\n* Signed informed consent form or in the case of patients unable to give consent, signature from the authorised representative\u002Flegal carevier or consultant.\n\nExclusion Criteria for the period of use of the Fasciotens Abdomen device:\n\n* Pregnancy or breast-feeding at the time of inclusion into the study\n* A Moribund patient with a life expectancy of less than 24 hours despite laparostomy\n* Unstable thorax or known severe skeletal instability which impaires the use of the fasciotens abdomen device.\n* Open wounds or infections at the potential contact points of the Fasciotens abdomen device\n* Known cardiac insufficiency with ejection fraction less than 35%\n* Patients with lung failure (ARDS) and the need for abdominal positioning within the next 24h\n\nExclusion criteria for the entire duration of the study:\n\n* Persons who are accommodated in a mental hospital or an insititution on official or judicial instruction\n* Persons who are dependent on or have an employment relationship with the principal investigator\n* Other conditions which, at the judgement of the investigator, militate against the use of the investigational product\n* Minority",{"count":109,"type":20},[56],"The open abdomen can occur as a result of various diseases. After infections of the abdomen, compartment syndromes or traumata, it is essential for survival (1). This condition of the open abdomen lasts from days to months. Within a very short time, the fascia and abdominal wall structures retract in such a way that direct abdominal closure is often impossible. In addition, there is a pronounced intraabdominal oedema, which additionally increases the space required by the abdominal organs. Therefore, it is clinically indispensable to increase the space of the intraabdominal organs in this life-threatening situation. After the laparotomy (opening of the abdomen) has been performed, it is therefore not closed. However, the natural traction on the abdominal wall, in particular on the fascia, the attached musculature as well as skin and subcutis, no longer exists in this situation. As a result, these structures retract over the period of the existing laparostoma.\n\nIn the present study, the CE-certified medical device Fasciotens Abdomen will be used to prove the functionality of this device and the user feasibility.\n\nThe basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. The possibility to apply a traction to the fascia from the moment of opening the abdomen without reducing the intraabdominal space is absolutely new and the rationale of this technique. The objective of this study is to prove the obvious prevention of fascial retraction through the Fasciotens Abdomen device.",[360,361,362,26],"Abdominal Compartment Syndrome","Pancreatitis,Acute Necrotizing","Intraabdominal Hypertension",[364],"Laparotomy, open abdomen, fascia, retraction, intraabdominal oedema","2023-04-17",{"date":367,"type":36},"2023-04-19",{"date":369,"type":36},"2019-08-05",{"date":371,"type":20},"2026-08",{"name":42,"class":43},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":380,"maxAge":4,"enrollmentInfo":381,"targetDuration":382,"studyType":78,"phases":4,"briefSummary":383,"conditions":384,"keywords":389,"overallStatus":314,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":4},"100458299","individual-risk-profiles-for-adverse-drug-reactions-in-geriatric-patients-100458299","NCT05247814","Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients","Individual Patient Risk Profiles for Adverse Drug Reactions: Establishing a Consecutive Research Cohort in an Interdisciplinary Polypharmacy Consultation Service of a Geriatric University Outpatient Department","Inclusion Criteria:\n\n* 70 years or older\n* Current drug therapy with three or more drugs\n* Being a patient in the interdisciplinary polypharmacy consultation service of the geriatric university outpatient clinic\n* Sufficient mobility (minimum: Wheelchair mobility)\n* Written informed consent of the patient or the legal representative\n\nExclusion Criteria:\n\n* No sufficient communication possible\n* Patients classified as terminally ill by the medical staff\n* Patients, that are incapable to give their informed consent and who do not have a legal representative","70 Years",{"count":255,"type":20},"6 Months","This project will generate a prospective cohort of geriatric patients with polypharmacy which will be characterized for vulnerability profiles of adverse drug reactions.",[385,386,387,388],"Polypharmacy","Pharmacogenetics","Pharmacogenomic Testing","Drug-Related Side Effects and Adverse Reactions",[390,391,392,393,394,395,396,397,398,399,400,401],"Geriatric Assessment","Medication Adherence","Aged","Aged, 80 and over","Medication therapy management","Pharmacists","Geriatricians","Clinical Pharmacology","Medication reconciliation","Hospital pharmacy services","Hospital outpatient clinics","nterdisciplinary Health Team","2022-06-17",{"date":404,"type":36},"2022-06-23",{"date":406,"type":20},"2022-07",{"date":408,"type":20},"2032-02",{"name":42,"class":43},{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":418,"targetDuration":420,"studyType":78,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":67},"100286882","development-of-a-biological-database-in-the-field-of-operative-intensive-care-100286882","NCT03014427","Development of a Biological Database in the Field of Operative Intensive Care","Development of a Biological Database in the Field of Operative Intensive Care for the Recording of Clinically Relevant Parameters of Critically Ill Intensive Patients","Biobank OIM","Inclusion Criteria:\n\n* patients after admission to the intensive care unit\n* 18 years or older\n* signed informed consent\n\nExclusion Criteria:\n\n* No exclusion criteria are formulated with regard to the objective of the register to record intensive care patients in general. Patients with multiple comorbidities, organ dysfunctions, and non-compliance for a curatively-intended therapy should also be recorded in the register. A palliative treatment or decision for best supportive care is not an exclusion criterion for registering.",{"count":419,"type":20},99999999,"10 Days","The storage and use of biomaterial samples is an important requirement for accompanying research and the acquisition of new knowledge to improve prognosis and therapy. Biobanking is explicitly recommended in official guidelines. In order to preserve the biomaterial, the patient must consent to the removal, transfer and storage of the biomaterial separately from the consent to the register. The biomaterial is taken at times at which a blood or urine sampling takes place anyway in the clinical routine. Therefore no additional interventions are necessary.",[423],"Intensive Care in General","2019-09-17",{"date":426,"type":36},"2019-09-18",{"date":428,"type":36},"2017-03-01",{"date":430,"type":20},"2050-02",{"name":42,"class":43},{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":439,"targetDuration":441,"studyType":78,"phases":4,"briefSummary":442,"conditions":443,"keywords":445,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":455,"locationsCount":67},"100246621","database-of-tissue-samples-to-understand-the-inflammatory-response-after-cardiac-surgery-100246621","NCT02488876","Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery","Non-individual Related Ongoing Collection of Blood Samples for the Compilation of a Unique Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery","Inclusion Criteria:\n\n* Patients undergoing cardiac surgery\n\nExclusion Criteria:\n\n* None.",{"count":440,"type":20},1000,"7 Days","The aim of this study is to collect non-individual related blood samples for the compelling of a unique database of tissue samples to understand the inflammatory responds after cardiac surgery on an on-going basis. This includes especially protein analyses and genetic testing for certain neurotransmitters in the blood and tissues to understand disease markers related to heart disease. The study is designed as an openly recruiting biobank with the purpose to later serve multiple study purposes. Outcomes refer to protein analyses and genetic testing for neurotransmitters in the blood and tissues.",[444],"Heart Diseases",[446,447,448],"Cardiac surgery","Tissue sample database","Inflammatory responds","2017-10-02",{"date":451,"type":36},"2017-10-03",{"date":453,"type":4},"2009-04",{"date":96,"type":20},{"name":42,"class":43},""]